Healthcare Industry News:  ImClone Systems 

Biopharmaceuticals Personnel

 News Release - June 2, 2006

Human Genome Sciences Names Margery B. Fischbein Vice President, Business Development & Strategic Planning

ROCKVILLE, Md., June 2 (HSMN NewsFeed) -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today announced that Margery B. Fischbein has joined the Company as Vice President, Business Development and Strategic Planning. Ms. Fischbein, formerly Vice President of Business Development at ImClone Systems Incorporated, will report to Barry A. Labinger, Executive Vice President and Chief Commercial Officer.

"Margery brings extensive experience in the identification, evaluation and negotiation of business development opportunities, and a broad range of well established relationships in the pharmaceutical and biotechnology industries," said Mr. Labinger. "She will be a strong addition to the HGS leadership team. As we continue our progress toward commercialization, Margery's skills and experience will allow her to play a critically important role in helping us advance our partnering objectives and strategic planning."

Ms. Fischbein has more than 25 years of experience in business development, strategic planning and corporate finance, with a strong focus in biopharmaceuticals. Prior to joining Imclone as Vice President of Business Development in 2004, she held senior positions with a number of leading firms, including Moody's Investors Service, Citigroup, JP Morgan Chase, and Lehman Brothers. Ms. Fischbein received her M.B.A. from Harvard Business School and her B.A. from Harvard University in Economics, graduating magna cum laude. She is a Board Member and past President of the Harvard Business School Club of New York.

About Human Genome Sciences

The mission of Human Genome Sciences is to discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs. For more information about Human Genome Sciences, please visit the company's web site at

HGS and Human Genome Sciences are trademarks of Human Genome Sciences.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with planned facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

Source: Human Genome Sciences

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.